SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Litière S.)
 

Sökning: WFRF:(Litière S.) > Characterization of...

  • Cardoso, F.Champalimaud Foundation,European Organisation for Research and Treatment of Cancer (författare)

Characterization of male breast cancer : Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2018

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:d42480f5-a52a-4d4a-b48a-039d951d25f1
  • https://lup.lub.lu.se/record/d42480f5-a52a-4d4a-b48a-039d951d25f1URI
  • https://doi.org/10.1093/annonc/mdx651DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:137682396URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: Male breast cancer (BC) is rare, managed by extrapolation from female BC. The International Male BC Program aims to better characterize and manage this disease. We report the results of part I, a retrospective joint analysis of cases diagnosed during a 20-year period. Methods: Patients with follow-up and tumor samples, treated between 1990 and 2010, in 93 centers/9 countries. Samples were centrally analyzed in three laboratories (the United Kingdom, the Netherlands and the United States). Results: Of 1822 patients enrolled, 1483 were analyzed; 63.5% were diagnosed between 2001 and 2010, 57 (5.1%) had metastatic disease (M1). Median age at diagnosis: 68.4 years. Of 1054 M0 cases, 56.2% were node-negative (N0) and 48.5% had T1 tumors; 4% had breast conserving surgery (BCS), 18% sentinel lymph-node biopsy; half received adjuvant radiotherapy; 29.8% (neo)adjuvant chemotherapy and 76.8% adjuvant endocrine therapy (ET), mostly tamoxifen (88.4%). Per central pathology, for M0 tumors: 84.8% ductal invasive carcinomas, 51.5% grade 2; 99.3% estrogen receptor (ER)-positive; 81.9% progesterone receptor (PR)-positive; 96.9% androgen receptor (AR)-positive [ER, PR or AR Allred score ≥ 3]; 61.1% Ki67 expression low (<14% positive cells); using immunohistochemistry (IHC) surrogates, 41.9% were Luminal-A-like, 48.6% Luminal-B-like/HER-2-negative, 8.7% HER-2-positive, 0.3% triple negative. Median follow-up: 8.2 years (0.0-23.8) for all, 7.2 years (0.0-23.2), for M0, 2.6 years (0.0-12.7) for M1 patients. A significant improvement over time was observed in age-corrected BC mortality. BC-specific-mortality was higher for men younger than 50 years. Better overall (OS) and recurrence-free survival (RFS) were observed for highly ER+(P=0.001), highly PR+(P=0.002), highly AR+ disease (P=0.019). There was no association between OS/RFS and HER-2 status, Ki67, IHC subtypes nor grade. Conclusions: Male BC is usually ER, PR and AR-positive, Luminal B-like/HER2-negative. Of note, 56% patients had T1 tumors but only 4% had BCS. ER was highly positive in > 90% of cases but only 77% received adjuvant ET. ER, PR and AR were associated with OS and RFS, whereas grade, Ki67 and IHC surrogates were not. Significant improvement in survival over time was observed.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Bartlett, J. M.S.University of Edinburgh,Ontario Institute for Cancer Research,Erasmus University Medical Center,Dutch Breast Cancer Research Group (BOOG),Memorial Sloan-Kettering Cancer Center (författare)
  • Slaets, L.European Organisation for Research and Treatment of Cancer (författare)
  • van Deurzen, C. H.M.Erasmus University Medical Center,Weill Cornell Medical College,Memorial Sloan-Kettering Cancer Center (författare)
  • van Leeuwen-Stok, E.Dutch Breast Cancer Research Group (BOOG) (författare)
  • Porter, P.Fred Hutchinson Cancer Research Center,University of Washington (författare)
  • Linderholm, B.Karolinska Institutet,Sahlgrenska University Hospital,Lund University (författare)
  • Hedenfalk, I.Lund University,Lunds universitet,Bröst- och ovarialcancer,Forskargrupper vid Lunds universitet,Bröst/ovarialcancer,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breast and Ovarian Cancer Genomics,Lund University Research Groups,Breast/ovarian cancer,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-ifa (författare)
  • Schröder, C.University Medical Center Groningen,Dutch Breast Cancer Research Group (BOOG) (författare)
  • Martens, J.Erasmus University Medical Center,Dutch Breast Cancer Research Group (BOOG) (författare)
  • Bayani, J.Ontario Institute for Cancer Research (författare)
  • van Asperen, C.Leiden University Medical Centre,Dutch Breast Cancer Research Group (BOOG) (författare)
  • Murray, M.Memorial Sloan-Kettering Cancer Center,St Wojciechs Hospital (författare)
  • Hudis, C.Weill Cornell Medical College,Memorial Sloan-Kettering Cancer Center (författare)
  • Middleton, L.University of Texas (författare)
  • Vermeij, J.Ziekenhuis Netwerk Antwerpen (ZNA) (författare)
  • Punie, K.University Hospitals Leuven (författare)
  • Fraser, J.Beatson West of Scotland Cancer Centre (författare)
  • Nowaczyk, M.St Wojciechs Hospital (författare)
  • Rubio, I. T.Vall d'Hebron University Hospital (författare)
  • Aebi, S.SAKK Coordinating Center (författare)
  • Kelly, C.All Ireland Cooperative Oncology Research Group (ICORG),European Organisation for Research and Treatment of Cancer (författare)
  • Ruddy, K. J.Mayo Clinic Minnesota (författare)
  • Winer, E.Dana-Farber Cancer Institute (författare)
  • Nilsson, C.Västmanland Hospital (författare)
  • Dal Lago, L.Institut Jules Bordet (författare)
  • Korde, L.University of Washington (författare)
  • Benstead, K.Cheltenham General Hospital (författare)
  • Bogler, O.University of Texas (författare)
  • Goulioti, T.Breast International Group (författare)
  • Peric, A.European Organisation for Research and Treatment of Cancer (författare)
  • Litière, S.European Organisation for Research and Treatment of Cancer (författare)
  • Aalders, K. C.European Organisation for Research and Treatment of Cancer (författare)
  • Poncet, C.European Organisation for Research and Treatment of Cancer (författare)
  • Tryfonidis, K.European Organisation for Research and Treatment of Cancer (författare)
  • Giordano, S. H.University of Texas (författare)
  • Champalimaud FoundationEuropean Organisation for Research and Treatment of Cancer (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Annals of Oncology: Elsevier BV29:2, s. 405-4171569-80410923-7534

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy